A Multicenter, Postmarketing Observational Study to Evaluate Safety Regarding Amyloid-Related Imaging Abnormalities and Their Management in Patients With Early Alzheimer's Disease and Treated With Lecanemab
概览
- 阶段
- 不适用
- 干预措施
- No Intervention
- 疾病 / 适应症
- Alzheimer's Disease
- 发起方
- Eisai Co., Ltd.
- 入组人数
- 5000
- 试验地点
- 3
- 主要终点
- Number of Participants With Amyloid Related Imaging Abnormality-Oedema/Effusion (ARIA-E) and Amyloid Related Imaging Abnormality-Microhemorrhage and Hemosiderin Deposit, and Cerebellar Microhaemorrhage (ARIA-H)
- 状态
- 招募中
- 最后更新
- 3个月前
概览
简要总结
The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.
研究者
入排标准
入选标准
- •All participants who are treated with lecanemab in routine clinical practice
排除标准
- 未提供
研究组 & 干预措施
All Participants
Participants prescribed lecanemab by a physician in routine clinical practice (post-marketing surveillance) will be observed prospectively for up to a maximum of 156 weeks or to the time of discontinuation, whichever occurs first.
干预措施: No Intervention
结局指标
主要结局
Number of Participants With Amyloid Related Imaging Abnormality-Oedema/Effusion (ARIA-E) and Amyloid Related Imaging Abnormality-Microhemorrhage and Hemosiderin Deposit, and Cerebellar Microhaemorrhage (ARIA-H)
时间窗: Up to 156 weeks
Number of Participants With Interruption or Discontinuation of Lecanemab After Onset of ARIA
时间窗: Up to 156 weeks
次要结局
- Number of Participants With Infusion Related Reaction(Up to 156 weeks)